ASTRO 2022: Focus on Prostate Cancer
ASTRO 2022: Focus on Prostate Cancer
Advertisement
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 25, 2022
RGPT is reliable in terms of safety and short-term clinical outcomes in patients with prostate cancer.
Read More
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 25, 2022
Researchers assessed the kinetics of PSMA PET uptake in prostate cancer lesions following radiation therapy.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 25, 2022
HDR brachytherapy as a salvage local therapy in prostate cancer has pros and cons.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 25, 2022
Researchers observed that patients with prostate cancer with high ATM have worse outcomes.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 24, 2022
A study compared the use of different radiation therapy (RT) techniques in prostate cancer.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 24, 2022
Dose-intensified radiation therapy does not yield increased survival in prostate cancer compared with today treatment.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 24, 2022
The risk of biochemical failure (BF) increases over time for patients with prostate cancer initially treated with radiation.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 24, 2022
A new study shows that lower facility-level PSA rates are linked with higher rates of metastatic prostate cancer.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 24, 2022
A study assessed Ga-68-PSMA PET/CT as a biomarker in prostate cancer.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 24, 2022
A study identified the optimal androgen deprivation therapy (ADT) duration to enhance survival in prostate cancer.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 24, 2022
PSMA PET is an important tool for postoperative treatment planning in prostate cancer (PCa) according to a study.
Advertisement
Advertisement
Advertisement